Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07160335 · ClinicalTrials.gov registry record · Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Shanghai Henlius Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
- 20
- Study locations
NCT07160335 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by Shanghai Henlius Biotech. The registered enrollment target is 174 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT07160335, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by Shanghai Henlius Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).
Conditions Studied
Interventions
- DRUG HLX17
- DRUG US-sourced Keytruda®
Study Locations (20)
California
- Oncology Physicians Network (OPN) - Glendale - Glendale
- Oncology Physicians Network (OPN)- Los Alamitos - Los Alamitos
- HCA - Los Angeles
- Los Angeles Cancer Network - Los Angeles
- Oncology Physicians Network (OPN) - San Bernardino - San Bernardino
Florida
- BRCR Global - Deerfield Beach
- D&H National Research Center - Margate
- Ocala Oncology - Ocala
- Mid Florida Hematology and oncology Center - Orange City
Washington
- American Oncology Network Vista Oncology Division - Olympia
- Northwest Medical Specialties PPLC (P1 Trials - Exigent Network ) - Tacoma
Anhui
- The First Affiliated Hospital of Anhui Medical University - Hefei
- The First Affiliated Hospital of Wannan Medical College - Wuhu
Fujian
- Fujian Cancer Hospital - Fuzhou
- The First Affiliated Hospital of Xiamen University - Xiamen
Texas
- Oncology Consulatants (P1 Trials -Exigent Network) - Houston
Beijing Municipality
- Beijing Chest Hospital, Capital Medical University - Beijing
Changsha
- Hunan Provincial Cancer Hospital - Hunan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2028-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07160335
The ClinicalTrials.gov registry entry for NCT07160335 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Shanghai Henlius Biotech, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which HLX17 is the first listed.
NCT07160335 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT07160335 about?
NCT07160335 is a clinical study titled "A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors". This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell c...
What is the current status of trial NCT07160335?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2025-09-26. Estimated completion is 2028-03-27.
What conditions does trial NCT07160335 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma.
What interventions are being tested in trial NCT07160335?
The interventions under investigation include: HLX17 (DRUG), US-sourced Keytruda® (DRUG).
Who is sponsoring clinical trial NCT07160335?
This trial is sponsored by Shanghai Henlius Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07160335 being conducted?
This trial has 20 study locations across California, Florida, Texas, Washington, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.